Mycophenolic acid (Acidum mycophenolicum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Immunosuppressive drugs

Included in the formulation
  • Mayfortic®
    pills inwards 
    Novartis Pharma AG     Switzerland
  • Mycophenolic acid-TL
    pills inwards 
    TECHNOLOGY OF DRUGS, LTD.     Russia
  • Felomika
    pills inwards 
    Nanopharma Development, LLC     Russia
    • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    VED

    7 nosologies

    АТХ:

    L.04.A.A.06   Mycophenolic acid

    Pharmacodynamics:

    Selectively and reversibly inhibits inosine monophosphate dehydrogenase, blocks the synthesis of guanosine nucleotides. It has the most pronounced effect on T-lymphocytes. Inhibits the formation of antibodies by B-lymphocytes. Reduces the migration of lymphocytes to the centers of graft rejection and inflammation.

    Pharmacokinetics:

    After oral ingestion, up to 94% is absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is achieved after 0.8 hours. The connection with plasma proteins is 97%.

    Metabolism in the liver to inactive metabolites.

    The elimination half-life is 17.9 hours. Elimination by the kidneys in the form of inactive metabolites.

    Indications:

    It is used to prevent organ rejection and allogeneic transplants.

    ICD-10

    XXI.Z80-Z99.Z94   Presence of transplanted organs and tissues

    Contraindications:

    Stomach ulcer and duodenal ulcer in the period of exacerbation, individual intolerance, children under 18 years of age.

    Carefully:

    Hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - category D. Contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Inside, on an empty stomach or during meals: 2-3 grams per day for two meals.

    The highest daily dose: 3 g.

    The highest single dose: 1.5 g.

    Side effects:

    Central and peripheral nervous system: Dizziness, insomnia, depression, tremor, paresthesia, muscle hypertonicity, drowsiness.

    Respiratory system: cough, shortness of breath, pharyngitis, pleural effusion, pulmonary edema.

    Hemopoietic system: anemia, leukocytopenia, thrombocytopenia, polycythemia, leukocytosis.

    The cardiovascular system: Hypertension, tachycardia, atrial fibrillation, orthostatic hypotension, angina, sores.

    Digestive system: ulcerative stomatitis, nausea, vomiting, diarrhea, gastralgia, bleeding from the gastrointestinal tract, esophagitis, gastritis, weight gain.

    Musculoskeletal system: arthralgia, myalgia, calf muscle cramps, myasthenia gravis.

    Dermatological reactions: acne, carcinoma.

    Sense organs: amblyopia, nonspecific cataract.

    Urinary system: Infections of the lower urinary tract, nephrosclerosis, hydronephrosis, pyelonephritis,dysuria, hematuria, albuminuria.

    Reproductive system: decreased potency.

    Allergic reactions.

    Overdose:

    Increased side effects, most often from the gastrointestinal tract and peripheral blood (neutropenia).

    Treatment: dose reduction or drug withdrawal, symptomatic therapy.

    Interaction:

    Antacids reduce absorption.

    Kolestiramin reduces the concentration of mycophenolic acid in the blood plasma.

    With simultaneous use with acyclovir, the concentration of both drugs increases.

    Special instructions:

    Monitoring the composition of peripheral blood: with a decrease in the absolute number of neutrophils to 1500 / μl, the use of mycophenolic acid should be discontinued.

    In the treatment it is not recommended to drive vehicles and work with moving mechanisms.

    Instructions
    Up